Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Common Equity (2016 - 2025)

Historic Common Equity for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $702.3 million.

  • Iovance Biotherapeutics' Common Equity fell 920.13% to $702.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $702.3 million, marking a year-over-year decrease of 920.13%. This contributed to the annual value of $710.4 million for FY2024, which is 2151.71% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Common Equity stood at $702.3 million for Q3 2025, which was down 920.13% from $698.5 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Common Equity registered a high of $773.5 million during Q3 2024, and its lowest value of $578.6 million during Q2 2023.
  • Moreover, its 3-year median value for Common Equity was $698.5 million (2025), whereas its average is $691.4 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 3283.46% in 2024, then plummeted by 920.13% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Common Equity (Quarter) stood at $584.6 million in 2023, then rose by 21.52% to $710.4 million in 2024, then decreased by 1.14% to $702.3 million in 2025.
  • Its last three reported values are $702.3 million in Q3 2025, $698.5 million for Q2 2025, and $767.9 million during Q1 2025.